<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03063515</url>
  </required_header>
  <id_info>
    <org_study_id>20161065</org_study_id>
    <nct_id>NCT03063515</nct_id>
  </id_info>
  <brief_title>AchE Inhibitor and Insulin</brief_title>
  <acronym>AchE</acronym>
  <official_title>Using Acetylcholinesterase Inhibitors to Promote Insulin Secretion in Human Beings</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Diabetes Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigator will examine the effect of a single dose of pyridostigmine, AchE inhibitor
      on insulin secretion in healthy subjects. Each subject will undergo an intravenous glucose
      tolerance test (IVGTT) where IV glucose will be administered and the glucose excursion and
      insulin secretion response will be evaluated by measuring insulin and glucose at different
      time points. The test will be carried out twice, once without and once with the
      administration of a single dose of Pyridostigmine on two separate days. The investigator
      hypothesizes that inhibiting AChE will potentiate insulin secretion.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 19, 2017</start_date>
  <completion_date type="Anticipated">June 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>First phase insulin response to IV glucose infusion</measure>
    <time_frame>-10, -4, 1, 2, 3, 4, 5, 6, 8, and 10 minutes</time_frame>
    <description>Insulin positive incremental area under the curve and the sum of plasma insulin values at 1 minute and 3 minutes after IV glucose infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucose excursion after IV glucose infusion</measure>
    <time_frame>-10, -4, 1, 2, 3, 4, 5, 6, 8, and 10 minutes</time_frame>
    <description>Glucose positive incremental area under the curve</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>IVGTT without pyridostigmine</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>An intravenous glucose tolerance test (IVGTT) will be performed without any medication for baseline comparison.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IVGTT with pyridostigmine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>An IVGTT will be performed 2 hours after taking one single dose of pyridostigmine 60 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyridostigmine</intervention_name>
    <description>single oral dose of 60 mg pyridostigmine tablet</description>
    <arm_group_label>IVGTT with pyridostigmine</arm_group_label>
    <other_name>Mestinon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years and older

        Exclusion Criteria:

          -  BMI &gt;30 Kg/m2

          -  fasting glucose &gt;100

          -  Glycohemoglobin (Hemoglobin A1C) 5.7% or more

          -  History of asthma

          -  Use of medications that may interfere with glucose metabolism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria del Pilar Solano, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria Solano</last_name>
    <phone>305-243-6145</phone>
    <email>msolano@med.miami.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Diabetes Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Solano</last_name>
      <phone>305-243-6145</phone>
    </contact>
    <investigator>
      <last_name>Maria del Pilar Solano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2017</study_first_submitted>
  <study_first_submitted_qc>February 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2017</study_first_posted>
  <last_update_submitted>August 30, 2017</last_update_submitted>
  <last_update_submitted_qc>August 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Maria del Pilar Solano</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Insulin secretion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Pyridostigmine Bromide</mesh_term>
    <mesh_term>Cholinesterase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

